跳至主要内容
临床试验/NCT04719000
NCT04719000招募中4 期

PErsonalized Addition of Recombinant LH in Suboptimal Responders >35 Years Old (POSEIDON Group 2): A Randomized Controlled Trial

Fundación Santiago Dexeus Font1 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2021年2月4日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
招募中
发起方
入组人数
120
试验地点
1
主要终点
Serum progesterone levels on the day of ovulation triggering.

研究概览

简要总结

Different ovarian stimulation regimens have shown to modify late follicular phase hormonal profiles. Besides, recent studies confirm that progesterone levels and their variation in the last day of oocyte maturation are affected by the dose of gonadotropins administered and by other factors. Progesterone elevation in late follicular phase of in vitro fertilization/intracytoplasmatic sperm injection (IVF/ICSI) cycles under ovarian stimulation compromises implantation rates due to a negative effect on the endometrium. However, there is still conflict in the literature questioning whether progesterone levels alone on the triggering day is a sufficient indicator as progesterone does not give the full picture of the ovarian functions, number of follicles as well as estrogen production that facilitate endometrial growth, thus some studies suggest that especially in aged and poor responders Progesterone/Estrogen (P4/E2) ratio has a better reflection (Progesterone (ng/mL) ×1,000/estradiol(pg/mL)) on the ovarian function.

The scope of the current pilot study is to compare serum progesterone levels as well as P4/E2 ratio on the day of ovulation triggering of women belonging to POSEIDON category group 2 who undergo a new ovarian stimulation with a dose of rhFSH 300 IU or 300 IU rhFSH plus 150 IU recombinant human luteinizing hormone (rhLH) in a gonadotropin-releasing hormone (GnRH) antagonist protocol.

详细描述

The main objective of assisted reproductive technology is to achieve a healthy child. Many aspects play a role in order to reach this outcome, including female age, the number of oocytes retrieved after ovarian stimulation, and endometrial receptivity. It has been clearly demonstrated that the number of oocytes obtained after ovarian stimulation for IVF/ICSI is a surrogate marker for the success rates following treatment. In general, a high number of oocytes retrieved is translated into a high number of embryos and eventually a high cumulative pregnancy rate (after the transfer of fresh and frozen-thawed embryos). However, although a higher number of oocytes and embryos may ensure an increase in the cumulative pregnancy rate, excessive ovarian response has been postulated to have a detrimental effect on the pregnancy rates following fresh embryo transfer given that raised serum estradiol and progesterone levels associated with a very excessive response may negatively affect embryo implantation.

In assisted reproductive technology (ART) cycles under the GnRH analog regimens, elevated progesterone serum levels at the late follicular phase, in good ovarian reserve women, is thought to be related to multiple follicular development and increased ovarian steroidogenic activity. However, for these patients elevated progesterone was shown to negatively affect the endometrium preparation and thereby implantation rate. Furthermore, in this group of women elevated progesterone is advocated to have no negative effect on the oocyte or embryo quality.

Importantly, more pronounced effect on unbalanced steroidogenesis has been correlated with age and ovarian reserve. For this patient population, serum progesterone/estradiol (P/E2) ratio on the day of human chorionic gonadotropin (hCG) administration was suggested as a more reliable marker predictor to cycle success than solely progesterone rise.

Based on the above-mentioned reports it is relatively clear that the aim of ovarian stimulation should be to result in high oocyte yield and educate endocrine milieu in order to maximize cumulative live birth rates. Nevertheless, despite this goal, a substantial proportion of patients do not manage to reach an optimal oocyte yield, resulting in lower pregnancy rates. These hypo-responders are associated with low follicles growth and reduced estrogen production leading to longer stimulations, and/or greater cumulative FSH doses.

Although, it is widely accepted that poor ovarian responders have significantly low live birth rates as compared with all other groups, an intermediate group of women with a "suboptimal ovarian response", has been recently proposed as a distinct group with significantly worse prognosis from women with normal response. In the same line, the POSEIDON group (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number) has recently proposed a new stratification for patients with a reduced ovarian reserve or unexpected inappropriate ovarian response to ovarian stimulation, taken into account quantitative and qualitative parameters such as: i. Age and the expected aneuploidy rate; ii. Ovarian biomarkers (mainly antral follicle count (AFC) and anti-Müllerian hormone (AMH)), and iii. Ovarian response to a previous stimulation cycle.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
35 Years 至 40 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Able and willing to sign the Patient Consent Form and adhere to study visitation schedule.
  • ≥ 35 years ≤40 years old.
  • AFC ≥5 and or AMH ≥1.2 ng/mL.
  • <4 or 4-9 oocytes retrieved in a previous IVF/ICSI cycle with a starting dose of ≤225 IU with any gonadotropin under a GnRH antagonist protocol.
  • Up to 3 previous ovarian stimulation cycles with a starting dose of ≤225 IU in which dose adjustments during stimulation did not exceed 300 IU.
  • Ovarian stimulation for IVF/ICSI

排除标准

  • Poor ovarian responders according to the Bologna criteria.
  • Polycystic ovary syndrome (PCOS) patients according to the Rotterdam criteria.
  • Age >40 or <35 years old.
  • Women with >10 oocytes retrieved in a previous IVF/ICSI cycle with 150-225 IU starting dose.
  • Women who required dose adjustments during stimulation >300 IU with any gonadotropin in their previous cycle
  • Uterine abnormalities.
  • Recent history of any current untreated endocrine abnormality.
  • Unilateral or bilateral hydrosalpinx (visible on ultrasound scan (USS), unless clipped).
  • Contraindications for the use of medicine used for ovarian stimulation (gonadotropins, GnRH antagonist, progesterone vaginal gel)
  • Recent history of severe disease requiring regular treatment (Clinically significant concurrent medical condition that could compromise subject safety or interfered with the trial assessment and patients with any contraindication to pregnancy).
  • Preimplantation Genetic Testing for Aneuploidies (PGT-a).
  • Testicular Sperm Aspiration or Testicular Sperm Extraction (TESA or TESE)

研究组 & 干预措施

rhFSH+rhLH

Experimental

Ovarian Stimulation with rhFSH+rhLH

干预措施: rhFSH+rhLH (Drug)

rhFSH

Active Comparator

Ovarian Stimulation with rhFSH

干预措施: rhFSH (Drug)

结局指标

主要结局

Serum progesterone levels on the day of ovulation triggering.

时间窗: 5 -20 days from initiation of ovarian stimulation

The outcome will be evaluated on the day of ovulation triggering

P/E2 ratio

时间窗: 5 -20 days from initiation of ovarian stimulation

Progesterone / estradiol ratio

次要结局

  • Values of Progesterone-to-follicle Index (PFI)(on the day of ovulation triggering.)
  • P/E2 ratio Profile(days 1, 6, 8, 10 and the day of ovulation triggering)
  • Estradiol Profile(days 1, 6, 8, 10 and the day of ovulation triggering)
  • FSH Profile(days 1, 6, 8, 10 and the day of ovulation triggering)
  • Testosterone Profile(days 1, 6, 8, 10 and the day of ovulation triggering)
  • Metaphase II (MII) oocytes retrieved(7 -20 days from initiation of ovarian stimulation)
  • Progesterone Profile(days 1, 6, 8, 10 and the day of ovulation triggering)
  • LH Profile(days 1, 6, 8, 10 and the day of ovulation triggering)
  • Oocytes retrieved(7 -20 days from initiation of ovarian stimulation)
  • Follicle to Oocyte Indexs (FOI)(7 -20 days from initiation of ovarian stimulation)
  • Percentage of patients with optimal number of oocytes retrieved (≥10 oocytes).(7 -20 days from initiation of ovarian stimulation)
  • Blastocyst formation rates (%).(Until 5, 6 or 7 days after insemination)
  • Follicular Output Rates (FORT)(Day 1 at the start of stimulation)
  • Percentage (%) of top-quality embryos(Until 5, 6 or 7 days after insemination)
  • Clinical pregnancy(at 6-7 weeks of gestation)
  • Ongoing pregnancy(at 8-9 weeks of gestation)
  • Biochemical pregnancy(2 weeks after embryo transfer)

研究者

发起方
Fundación Santiago Dexeus Font
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

PErsonalized Addition of Recombinant LH in Ovarian... | 临床试验